Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1998, p. 2569-2575, Vol. 42, No. 10
Institute of Medical Microbiology and
Hygiene,
Received 30 March 1998/Returned for modification 1 July
1998/Accepted 3 August 1998
A cytofluorometric assay that allowed assessment of damage to
phagocytosed Aspergillus fumigatus conidia at the
single-cell level was developed. After ingestion by monocyte-derived
macrophages (MDMs), conidia were reisolated by treatment of the
cells with streptolysin O, a pore-forming toxin with lytic properties
on mammalian cells but not on fungi. The counts obtained by staining of
damaged conidia with propidium iodide and quantification by cytofluorometry correlated with colony counts. By the use of this method, we demonstrate that MDMs differentiated in vitro by low-dose granulocyte-macrophage colony-stimulating factor and gamma
interferon have only a limited capacity to damage
Aspergillus conidia in vitro. The killing rate 12 h
after phagocytosis was found to be only 10 to 15%. However,
intracellular loading of the phagocytes with amphotericin B (AmB) dose
dependently enhanced the anticonidial activity. Preincubation of
macrophages with only 1 µg of AmB per ml resulted in an
uptake of 18 fg of AmB/cell, leading to killing rates of 50 to 60%.
The experimental protocol provides a new tool for the rapid
quantification of anticonidial activity against A. fumigatus in vitro. Intracellular accumulation of AmB may
represent an important factor underlying the efficacy of this
antifungal drug in the prophylaxis and treatment of
Aspergillus infections.
Aspergillus fumigatus is
becoming increasingly important as a causative agent of
life-threatening infections in immunocompromised hosts (for reviews,
see references 4, 5, 12, 21, and 34). During the last three decades, the number of
invasive Aspergillus infections has risen dramatically and
the incidence has been reported to vary between 5 and 19% in
transplantation patients (15, 19). A. fumigatus
is the most prominent pathogen in the Aspergillus family,
accounting for more than 90% of human Aspergillus
infections.
Amphotericin B (AmB) has remained the drug of choice for treatment.
However, the lethality of manifest infections remains high and the
toxicity of full-scale treatment is considerable (7, 8, 11).
This has prompted exploration of possibilities for the prophylactic use
of AmB, with the result that clinical regimens for low-dose intravenous
application are now available (28). Furthermore, the
possibility of aerosol application of AmB by inhalation has been
investigated (2, 23).
Uptake of conidia by the respiratory system is the initial event in
Aspergillus infections, with survival of conidia in
phagocytes and the onset of germination being requisites for
establishing disease. The reported ingestion and conidial killing
activities of alveolar macrophages are widely regarded as
central to the first line of defense (32). The mechanisms of
conidial elimination by macrophages are not fully understood
(for reviews, see references 30 and
31), and this may partly be due to a lack of methods for measuring conidial damage and killing. To quantify the killing, the
ingested conidia are usually liberated by lysis of phagocytes, and
viability is assessed either by microscopic observation of conidial
outgrowth (20, 32) or by performing colony count studies
(24, 38).
Previous studies have shown that in addition to its action against
extracellular fungi, AmB can accumulate intracellularly and enhance the
phagocytic killing of Candida albicans in vitro (18). Because AmB is the drug of choice for the
treatment of Aspergillus infection, we investigated whether
macrophages would also be able to accumulate AmB and
whether this would have an effect on damage to A. fumigatus
conidia.
In the course of this work, we developed a novel method based on
detergent-free reisolation of conidia from phagocytes, followed by flow
cytometric analysis with propidium iodide (PI), which is used to stain
dead conidia. This allowed quantification of conidial killing at the
level of a single conidium. We were unable to confirm
previous reports that had suggested efficient conidial elimination
by macrophages (24, 38). The killing capacity of
monocyte-derived macrophages differentiated in culture with low-dose granulocyte-macrophage colony-stimulating factor
(GM-CSF) and gamma interferon is surprisingly low but can be markedly
enhanced by preincubation and loading of the cells with nontoxic
concentrations of AmB.
Preparation of conidial suspensions.
Conidia were prepared
from strain ATTC 46645. After subculture on Sabouraud agar (Becton
Dickinson, Heidelberg, Germany), conidial suspensions were prepared as
described by Roilides et al. (25). In brief, the plates were
washed with a physiological saline solution (0.9% [wt/vol] NaCl),
and the conidial suspension was filtered twice through a sterile
40-µm-pore-size nylon mesh (Falcon, Heidelberg, Germany). Penicillin
(100 U/ml) and streptomycin (100 µg/ml) (antibiotic mix; Gibco,
Karlsruhe, Germany) were added, and the suspensions were stored at
4°C.
Preparation of MDMs.
Human monocytes were isolated from
buffy coats as described previously (16, 18) and were seeded
at a concentration of 1.5 × 106/ml/well in minimal
essential medium (MEM) containing 10% normal human serum (NHS) in
24-well plates (Nunc, Wiesbaden, Germany). Monocyte-derived
macrophages (MDMs) were obtained by culture for 5 to 7 days at
37°C in 5% CO2 in the presence of 2.5 ng of GM-CSF (Essex Pharma, Munich, Germany) per ml and 0.5 ng of gamma interferon (Gammaferon 50; Bioferon GmbH, Laupheim, Germany) per ml.
Drugs and reagents.
AmB was purchased from Squibbs Pharma,
Vienna, Austria, and was kept as a 5-mg/ml stock in distilled water at
Effects of SLO on metabolic activity of MDMs and conidia.
The potential damaging effects of SLO on either conidia or MDMs were
tested by a colorimetric test (13, 14). Conidia
(106/well) were incubated with SLO (20 µg/ml) in
PBS-0.1% BSA for 30 min. Thereafter, supernatants were carefully
aspirated and were replaced by 50 µl of RPMI 1640 (Biochrom, Berlin,
Germany) containing 0.5 mg of
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT;
Serva, Heidelberg, Germany) per ml and 100 µM menadione (Sigma).
Incubations were continued for another 3 h to allow the formation
of formazan by viable conidia (13). Formazan crystals were
dissolved by the addition of 150 µl of acidic isopropanol (95 ml of
isopropanol, 5 ml of 1 N HCl) per well and vigorous shaking for 10 min.
Aliquots of 150 µl were transferred to enzyme-linked immunosorbent
assay reader plates (Greiner, Nürtingen, Germany), and the amount
of formazan was measured immediately in a microplate reader (EAR400;
Salzburger Labortechnik, Crailsheim, Germany) at 550 nm. Wells without
conidia served as background controls. To determine the effects of SLO
on MDMs, metabolic activity in the cells was assessed in parallel by
phase-contrast microscopy. MDMs were incubated with SLO, supernatants
were aspirated and replaced by 50 µl of RPMI 1640 containing
MTT-menadione, and the assay was then continued as described above for
the conidia. The percentage of formazan formed was calculated by the
following equation: relative formazan formation = (ODs Measurement of cell-associated AmB.
AmB was quantified by
scanning spectrophotometry as originally described by Shihabi et al.
(33) with modifications for measurement of cell-associated
AmB as described by Martin et al. (18). In brief, MDMs
(3 × 106/well) were cultured in six-well culture
plates (Delta plate; Nunc, Wiesbaden, Germany). After overnight
incubation with AmB at 0.5 and 1.0 µg/ml in the culture medium, the
supernatants were discarded and the cells were carefully washed three
times with PBS. Then, 400 µl of acetonitrile was added to the wells.
After vigorous mixing, the cells were scraped off, the suspension was transferred to an Eppendorf tube, and the tube was centrifuged at
10,000 × g for 2 min. The supernatants were
transferred to quartz microcuvettes (Zeiss, Frankfurt on Main,
Germany), and scanning photometry was performed at wavelengths of 350 to 450 nm with a Ultrospec II photometer (Pharmacia LKB, Freiburg,
Germany) connected to a data processing unit. Calculations were
performed by linear regression analysis on the basis of standard curves for AmB.
AmB pretreatment of MDMs.
Prior to incubation with conidia,
the cells were incubated for 16 h in 1 ml of MEM-10% NHS
containing various concentrations of AmB ranging from 0.1 to 1.0 µg/ml. Subsequently, the cells were washed three times with 1 ml of
PBS (pH 7.3), and finally, 1 ml of MEM-10% NHS was added.
Incubation of MDMs with conidia and reisolation of conidia.
To each well containing MDMs, 1.5 × 106 conidia were
added and the plates were centrifuged at 200 × g for 5 min. After incubation for 12 h, the medium was removed and stored
at Quantification of conidial killing by colony counting.
For
each sample, aliquots corresponding to approximately 100 and 1,000 CFU
were plated in duplicate on Sabouraud agar plates containing 0.03%
deoxycholate, and the plates were incubated at 37°C for 36 h.
Colonies were counted under a stereomicroscope and a kill index (KI)
was calculated as 1 PI staining and cytofluorometry.
PI was added to the
reisolated conidial samples at a final concentration of 50 µg/ml.
After incubation for 20 min at room temperature the sample volume was
adjusted to 500 µl with PBS. Each sample was vigorously vortexed
before cytofluorometric measurement in a FACScan flow cytometer (Becton
Dickinson, Heidelberg, Germany). Acquisition was done with LysisII
Software (Becton Dickinson), and the parameters were E-01 for forward
scatter (FSC), 305 for side scatter (SSC), and 507 for the fluorescence
3 (FL-3) detector. A live gate was set for each experiment. A relative
FL-3 intensity above 101 was considered to reflect positive
PI staining, and a marker (M1) was set accordingly. The average
measurement time for 2,500 events within the gate corresponding FSC/SSC
characteristics was 15 s. Analysis was performed by using either
LysisII software or WINMDI, version 2.3, a public-domain
cytofluorometer analysis software package by J. Trotter
(http://facs.scripps.edu).
Statistical analysis.
Statistical analysis was performed
with Prism software (GraphPad Inc., San Diego, Calif.). Determination
of significance was done by a two-tailed Mann-Whitney test.
Effect of detergents on PI staining of conidia.
Existing
methods for reisolation of phagocytosed conidia include the use of
detergents (24, 27, 37, 38). Hence, we first attempted to
use deoxycholate as the lysis reagent. Resting conidia did not stain
with PI. Unexpectedly, however, if the conidia were first incubated for
several hours in medium to permit transition to the metabolically
active stage, exposure to deoxycholate caused them to stain positively
with PI. This is shown in Fig. 1. The same results were obtained when sodium dodecyl sulfate, Triton X-100,
or Nonidet P-40 (all at a 0.5% final concentration) was used. This
finding suggested that as the conidia became metabolically active, they
became sensitive to the actions of the detergents. As a consequence, to
exclude damaging effects on conidia during reisolation from
macrophages, detergent-free cell lysis procedures had to be
developed.
Reisolation of phagocytosed conidia from MDMs with the use of
SLO.
We turned to the use of an agent that would selectively
destroy mammalian cells while leaving fungi intact. SLO was chosen for
this purpose. In a first set of experiments monocytes or conidia were
incubated with SLO, and metabolic activity was assessed by the MTT
assay. Incubation of MDMs with SLO at concentrations of 1 to 20 µg/ml
for 10 min led to a dose-dependent reduction of MTT conversion. This
was paralleled by disintegration of the cells, as observed by
phase-contrast microscopy. In contrast, no effect on the metabolic
activity of conidia was detected (Fig.
2). By combining SLO treatment with
enzymatic digestion, the cells could be lysed extensively, so that
phagocytosed conidia were liberated, and these became detectable as a
single population by cytofluorometry. This is shown in a dot plot (Fig.
3A and B). The position within the plot
was identical to that of the conidia analyzed prior to phagocytosis
(Fig. 3A). The background, i.e., cell debris particles eliciting
signals within the live gate defined for conidia, was determined for
each experiment and ranged from 2 to 5% of the total counts, which was
considered negligible. No uptake of PI was seen by conidia that had
been incubated in medium for 4 h (Fig. 3C).
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Accumulation of Amphotericin B in Human Macrophages Enhances
Activity against Aspergillus fumigatus Conidia:
Quantification of Conidial Kill at the Single-Cell Level
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
20°C. Working solutions were prepared in water. Recombinant human
gamma interferon (Gammaferon 50; Bioferon GmbH) was diluted 1:100 in
phosphate-buffered saline (PBS)-0.1% human serum albumin (Behring,
Marburg, Germany) to yield a stock solution of 500 µg/ml which was
stored in portions (50 µl) at
70°C. Human recombinant GM-CSF
(Leukomax; Essex Pharma, Munich, Germany) was kept as 20-µl portions
of 25 mg/ml at
20°C. Streptolysin O (SLO) was prepared as described
previously (39), dissolved at a concentration of 2 mg/ml in
PBS-0.1% bovine serum albumin, and kept in 10-µl portions at
70°C. An RNase (R-6513) stock solution (1 mg/ml), a DNase stock
solution (2,000 kU/ml), and a proteinase K stock solution (20 mg/ml)
(all purchased from Sigma, Munich, Germany) were prepared in normal
saline and were kept at
20°C. Deoxycholate (Roth, Karlsruhe,
Germany) was prepared as a 5% (wt/vol) stock solution in distilled
water. Stock solutions of sodium dodecyl sulfate (5% [wt/vol]),
Triton X-100 (10% [vol/vol]), and Nonidet P-40 (5% [vol/vol]),
all purchased from Sigma, were prepared in distilled water and were
kept at room temperature.
ODb)/(ODC
ODb) × 100, where ODs is
the optical density of the sample, ODb is the
optical density of the background, and ODc is
the optical density of the control sample (without toxin).
20°C for later assessment of residual AmB activity. A total of
150 µl of 0.1% BSA containing SLO at a concentration of 20 µg/ml
was added to the wells, and the plates were incubated at 37°C for 30 min. The content of each well was drawn three times through an
Eppendorf pipette (200 µl), and the suspension was then transferred
to an Eppendorf tube and kept at 37°C. After rinsing with 100 µl of PBS, each well was checked for complete removal of cells by microscopic inspection. The tubes were transferred to an Eppendorf thermomixer (37°C), and the following components were added: MgCl2
and CaCl2, each to final concentration of 0.5 mM; 10 µl
of RNase (1 mg/ml); and 10 µl of DNase (2,000 kU/ml). The incubation
was then continued for 10 min. Subsequently, 3 µl of proteinase K (20 mg/ml) was added for another 10 min. Finally, the tubes were
transferred to a water bath sonifier (Bandelin Electronic, Berlin,
Germany) for 10 min and then kept on ice. An aliquot of 100 µl was
used for determination of the numbers of CFU, and the remaining
suspension was stored at 4°C overnight before being subjected to
cytofluorometric analysis. Cells incubated with conidia for 45 min to
allow phagocytosis only were used as controls for the overall viability
of the conidia. Wells containing MDMs only were treated as described
above and served as background controls in cytofluorometric
measurements.
(CFUs/CFUc), where
CFUs is the colony count of the respective
sample, and CFUc corresponds to the colony
counts of the phagocytosis control.
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

View larger version (22K):
[in a new window]
FIG. 1.
Deoxycholate promotes PI uptake in metabolically active
conidia. Conidia were incubated in MEM for 4 h at 37°C and were
then treated with deoxycholate (0.5%, 10 min, 23°C). When stained
with PI, the number of PI-positive conidia increased by 30% (
)
compared to the number of control conidia before culture (
). The PI
fluorescence intensity (FL-3) is plotted on the x axis
against the number of cells (events) on the y axis. The
marker (M1) defines the range of PI-positive conidia.

View larger version (28K):
[in a new window]
FIG. 2.
SLO affects metabolic activity in MDMs but not in
conidia. MDMs and conidia were incubated with SLO (20 µg/ml) in PBS-0.1% BSA for the indicated times (x axis).
Subsequently, the metabolic activity was assessed by formazan formation
(optical density at 550 nm; y axis) by a menadione-augmented
MTT test. The metabolic activity in MDMs (
) decreased by 90% but
was unaffected in conidia (
). A relative formazan formation
value of 1 corresponds to 100%; values are given as means ± standard errors of the means from three independent experiments. *,
P < 0.05.

View larger version (20K):
[in a new window]
FIG. 3.
Conidia can be liberated from phagocytes through lysis
with SLO: flow cytometric analysis. (A) A region (R1) was defined
according to the size (FSC) and granularity (SSC) characteristics of
the conidia. (B) After phagocytosis and an intracellular stay
for 12 h, the conidia were isolated from MDMs by a
combination of SLO lysis and mixing with enzymes. Conidia were detected
as a distinct population within R1 as defined in panel A, and 2,500 events/sample were gated. (C) After phagocytosis and reisolation as
described for panel B; PI staining and fluorescence-activated cell
sorter analysis were performed. Histogram analysis of the population
within region R1 (B) showed less than 8% PI-positive conidia,
as defined by a marker (M1). The numbers of conidia (events;
y axis) are plotted against PI fluorescence intensity (FL-3;
x axis).
Use of detergents to reisolate phagocytosed conidia creates killing artifacts. The pilot PI uptake experiments had suggested that detergents might damage metabolically active conidia, thus creating artifacts during reisolation procedures. This was confirmed by determination of the viability by obtaining colony counts for conidia reisolated from MDMs either by deoxycholate or by SLO treatment. When the detergent was used, a killing rate of approximately 90% (KI = 0.9) within 12 h after phagocytosis was observed. In contrast, much lower rates of killing (only 16% after 12 h and 27% after 24 h) were determined when the detergent-free procedure with SLO was used (Fig. 4). Thus, deoxycholate at concentrations required for solubilization damages A. fumigatus conidia unspecifically and cannot be used in these assays.
|
Accumulation of AmB in MDMs. The accumulation of AmB in MDMs was determined after pretreating the cells with 0.5 or 1.0 µg of AmB per ml for 14 h. The cell-associated AmB was quantified by wavelength scan photometry. As shown in Fig. 5, a dose-dependent uptake by MDMs was observed. Pretreatment of the cells with the antimycotic at a final concentration of 1 µg/ml led to an accumulation of approximately 14 fg of AmB per cell (Fig. 5).
|
Effect of cell-associated AmB on phagocytic killing of conidia as determined by flow cytometry. MDMs were first incubated with 1 µg of AmB per ml to allow intracellular AmB accumulation as described above. Subsequently, the conidia were added. After 12 h, the conidia were reisolated from the cells by the SLO lysis procedure. As controls, conidia were reisolated from the cells just after complete phagocytosis, i.e., after 45 min of incubation with MDMs. The reisolated conidia were stored overnight at 4°C and were then stained with PI. Overnight storage proved to be essential in order for PI uptake to be observed. The proportion of PI-positive conidia in controls was in the range of 6 to 9% (Fig. 6). For controls incubated for 45 min, the proportion of PI-positive conidia was 8.03% ± 0.01% (mean ± standard error of the mean; n = 4 independent experiments). Prolongation of the intracellular stay to 12 h increased the percentage of PI-positive conidia to 17.96% ± 0.06% (mean ± standard error of the mean of four independent experiments (Fig. 6).
|
Determination of anticonidial activity by colony counting. Colony counting, the "gold standard" for assessing conidial killing was performed with samples from the reisolated conidia. Aliquots were plated out directly at the end of the reisolation procedure. Each count was determined in duplicate. With untreated MDMs, a KI of 0.18 (median killing, 18%) was found (Fig. 7). In contrast, MDMs that had been preincubated with AmB for 14 h had much higher levels of anticonidial activity (Fig. 7). Augmentation of conidial killing was dependent on the drug concentration, and a maximum kill of 55% ± 7% was seen for cells that had been pretreated with 1 µg of AmB per ml. These results were similar to those obtained by the cytofluorometric assay (Fig. 6).
|
Correlation between cytofluorometric measurements and colony counting. Killing rates obtained in parallel from cytofluorometric measurement and colony count determinations were correlated. Data derived from 107 kill determinations formed the basis for statistical evaluation by linear regression analysis, shown as a regression curve (Fig. 8). A correlation coefficient of 0.81 was calculated (Fig. 8). The results of the statistical evaluation indicated a clear correlation between the conidial killing assessed either by cytofluorometry or by determination of the numbers of CFU.
|
| |
DISCUSSION |
|---|
|
|
|---|
Invasive pulmonary aspergillosis is a typical opportunistic infection in patients with sustained immunosuppression (4, 19, 34). AmB, the drug of choice, has considerable dose-related side effects, and despite adequate treatment, the rate of lethality remains high (5, 8, 11). Thus, the use of low-dose intravenous AmB has evolved as one strategy of prophylaxis (28). Furthermore, the local prophylactic administration of AmB at the port of entry, i.e., as an aerosol application to the lung, has also been reported (2, 23).
After the administration of therapeutic doses of AmB, the AmB accumulates in lung tissue, and the uptake of AmB by alveolar macrophages has been reported (1, 6). Previous studies by Martin and Bhakdi (16) demonstrated that AmB also accumulates in monocytes in vitro and that this enhances the ability of the cells to kill C. albicans in vitro. Here, we investigated whether macrophages would also be able to accumulate AmB in vitro and whether cell-associated AmB would have an effect on activity against the conidia of A. fumigatus, the main causative agent of invasive pulmonary aspergillosis.
Pulmonary alveolar macrophages are considered the first line of defense against Aspergillus conidia and are able to kill conidia in vitro (30-32). It has also been shown by Schaffner and colleagues (29, 32) that blood monocyte-derived macrophages from either rabbits or humans display comparable anticonidial activities (29, 32). Hence, human monocyte-derived macrophages have been used in in vitro studies with Aspergillus (20, 26, 29, 32, 38) and were also used as effector cells in our study. To obtain a constant degree of differentiation, low doses of gamma interferon and GM-CSF were present during culture.
Methods used to assess conidial killing are limited and involve either microscopic assessment of conidial germination (20, 32) or colony counting (24, 38). Microscopy is difficult to quantify, and determination of the numbers of CFU is tedious and time-consuming. Therefore, we developed a novel method based on cytofluorometry, which determines the level of killing at the single conidium level. Membrane permeability for PI was selected as the indicator for conidial damage. PI uptake can be detected by argon laser cytofluorometry and has been used for killing assessments with mammalian cells as well as fungal organisms, e.g., Candida (17, 35). Reisolation from phagocytes is a basic prerequisite for the assessment of conidial killing, and detergents have been used for this purpose (24, 38). However, we found that after transition of conidia from the dormant to the metabolically active state, PI uptake occurred upon treatment with deoxycholate, suggesting a damaging effect on the conidia.
Therefore, it became essential to develop a detergent-free reisolation procedure. To this end, the selective action of SLO on mammalian cells was exploited (3, 39). Exposure to SLO resulted in permeabilization and fragmentation of the phagocytes, paralleled by a sharp decline in their metabolic activity. In fungi, cholesterol is replaced by ergosterol (10); hence, the binding structure for SLO is absent. As expected, conidial metabolic activity and cell wall integrity were not affected by SLO.
The conidial killing rate 12 h after phagocytosis by untreated macrophages was in the range of 15 to 18% when the SLO reisolation method was used. This is in accordance with the killing rates derived from experiments in which hypotonic lysis with distilled water was used for reisolation (20, 29, 32). In contrast, colony counts for conidia reisolated by deoxycholate treatment indicated a much higher rate of killing (approximately 90%). Similar high killing rates (60%) after 2 to 3 h of phagocytosis have been found in other studies that used detergent lysis (24, 27, 37, 38). Our present data now indicate that the use of detergents can give rise to incorrect results. Hypotonic lysis with water is better, but it generates high levels of background cell debris so that cytofluorometry cannot be used to detect the conidia (data not shown). The SLO-based lysis procedure produced dispersed conidial suspensions, rendering these accessible to identification as a distinct population by flow cytofluorometry.
Preincubation of MDMs with AmB resulted in a dose-dependent cellular accumulation of the drug. The intracellular concentration, estimated on the basis of a cell volume of 500 fl and an amount of 14 fg/cell, was 7 µg/ml, which is in the therapeutic range (8, 11; unpublished observations). Similar results have been reported for human monocytes (18). The cellular accumulation of the antimycotic resulted in a marked increase in the percentage of PI-positive conidia. Notably, uptake of PI by the conidia was observed only after overnight incubation of the cells at 4°C. This finding suggested that breakdown of the membrane permeability barrier lagged behind the primary damaging event incurred by the phagocytes.
Conidial colony counts from AmB-pretreated MDMs were reduced correspondingly. Since a direct effect of AmB in the media was excluded by testing them for antifungal activity in a menadione-augmented MTT test (9, 13, 14) (data not shown), the observed enhancement of anticonidial activity must have been due to cell-associated AmB. This is in line with previous studies of Martin et al. (18) showing that the intracellular accumulation of AmB enhances the ability of the cells to kill C. albicans. To date, the effect of AmB on the antifungal properties of phagocytes has been studied exclusively with Candida. In their early studies, Perfect et al. (22) used much higher concentrations of AmB, and an indirect antifungal effect mediated by activation of the phagocytes was discussed. Martin et al. (18), however, have clearly shown that low-dose AmB pretreatment (the concentrations used in the present study) resulted in a marked increase in the candidacidal activity of human monocytes without activating the cells. The possibility of a direct antifungal effect of cell-associated AmB has also been implicated from results from studies by van Etten et al. (36), in which low-dose AmB (0.4 µg/ml) enhanced Candida killing by murine macrophages.
During cell culture, low-dose GM-CSF as well as gamma interferon were present, and both cytokines reportedly augmented the activity of monocytes against Aspergillus hyphae (26). In contrast, the anticonidial activity of MDMs is not influenced by gamma interferon (29; unpublished observations). To our knowledge, no studies are available on the effect of GM-CSF on conidial killing by MDMs. We share, however, an unpublished observation with Schaffner (31), who mentions that no significant change in the killing capability of MDMs can be induced by GM-CSF. Furthermore, the basal killing rates that we observed in MDMs are similar to the killing rates reported from studies in which no cytokines were present during in vitro differentiation. Thus, it can be assumed that the culture of freshly isolated monocytes with low-dose GM-CSF and gamma interferon does not significantly alter the basic anticonidial activity of MDMs. Whether or not cytokines may contribute to the increase in conidial killing after AmB accumulation in the phagocytes needs further investigation.
Conclusion. Reisolation of conidia after ingestion by phagocytes and assessment of PI uptake by cytofluorometry were established as novel methods for the quantification of conidial killing by phagocytes. This new tool obviates the exposure of conidia to detergents, which may have an intrinsic damaging effect on phagocytosed conidia.
The present study is the first to investigate the effect of cell-associated AmB on the conidia of A. fumigatus. The results indicate that the cellular accumulation of AmB enhances the ability of human macrophages to kill the fungus. Cell-associated AmB may be a factor contributing to the prophylactic and therapeutic efficacies of this antifungal drug against Aspergillus infections.| |
ACKNOWLEDGMENTS |
|---|
We thank M. Hussmann for helpful discussion.
This work was supported by the Ministerium für Umwelt und Forsten des Landes Rheinland-Pfalz.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute of Medical Microbiology and Hygiene, Hochhaus am Augustusplatz, D-55101 Mainz, Germany. Phone: 49-6131-172865. Fax: 49-6131-392359. E-mail: bjahn{at}mzdmza.zdv.uni-mainz.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Benson, J. M., and M. C. Nahata. 1988. Clinical use of systemic antifungal agents. Clin. Pharm. 7:424-438[Medline]. |
| 2. |
Beyer, J.,
G. Barzen,
G. Risse,
C. Weyer,
K. Miksits,
K. Dullenkopf,
D. Huhn, and W. Siegert.
1993.
Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis.
Antimicrob. Agents Chemother.
37:1367-1369 |
| 3. | Bhakdi, S., U. Weller, I. Walev, E. Martin, D. Jonas, and M. Palmer. 1993. A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes. Med. Microbiol. Immunol. Berlin 182:167-175[Medline]. |
| 4. | Bouchara, J. P., G. Tronchin, G. Larcher, and D. Chabasse. 1995. The search for virulence determinants in Aspergillus fumigatus. Trends. Microbiol. 3:327-330[Medline]. |
| 5. | Denning, D. W. 1994. Invasive aspergillosis in immunocompromised patients. Curr. Opin. Infect. Dis. 7:456-462. |
| 6. |
Edmonds, L. C.,
L. Davidson, and J. S. Bertino.
1991.
Effect of variation in infusion time and macrophage blockade on organ uptake of amphotericin B-deoxycholate.
J. Antimicrob. Chemother.
28:919-924 |
| 7. |
Ellis, M. E.,
A. A. al-Hokail,
H. M. Clink,
M. A. Padmos,
P. Ernst,
D. G. Spence,
W. N. Tharpe, and V. F. Hillier.
1992.
Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B.
Antimicrob. Agents Chemother.
36:172-179 |
| 8. | Fraser, I. S., and D. W. Denning. 1993. Empiric amphotericin B therapy: the need for a reappraisal. Blood Rev. 7:208-214[Medline]. |
| 9. | Garn, H., H. Krause, V. Enzmann, and K. Drossler. 1994. An improved MTT assay using the electron-coupling agent menadione. J. Immunol. Methods 168:253-256[Medline]. |
| 10. | Griffin, D. H. 1994. Fungal physiology, p. 23-62. Wiley-Liss, New York, N.Y. |
| 11. | Hoeprich, P. D. 1992. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin. Infect. Dis. 14(Suppl. 1):S114-S119. |
| 12. | Holden, D. W., C. M. Tang, and J. M. Smith. 1994. Molecular genetics of Aspergillus pathogenicity. Antonie Leeuwenhoek 65:251-255. |
| 13. | Jahn, B., E. Martin, A. Stüben, and S. Bhakdi. 1995. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J. Clin. Microbiol. 33:661-667[Abstract]. |
| 14. | Jahn, B., A. Stüben, and S. Bhakdi. 1996. Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar Blue tests. J. Clin. Microbiol. 34:2039-2041[Abstract]. |
| 15. |
Kramer, M. R.,
S. E. Marshall,
V. A. Starnes,
P. Gamberg,
Z. Amitai, and J. Theodore.
1993.
Infectious complications in heart-lung transplantation. Analysis of 200 episodes.
Arch. Intern. Med.
153:2010-2016 |
| 16. |
Martin, E., and S. Bhakdi.
1991.
Quantitative analysis of opsonophagocytosis and of killing of Candida albicans by human peripheral blood leukocytes by using flow cytometry.
J. Clin. Microbiol.
29:2013-2023 |
| 17. |
Martin, E.,
F. Maier, and S. Bhakdi.
1994.
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum.
Antimicrob. Agents Chemother.
38:1331-1338 |
| 18. |
Martin, E.,
A. Stüben,
A. Gorz,
U. Weller, and S. Bhakdi.
1994.
Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.
Antimicrob. Agents Chemother.
38:13-22 |
| 19. | McWhinney, P. H., C. C. Kibbler, M. D. Hamon, O. P. Smith, L. Gandhi, L. A. Berger, R. K. Walesby, A. V. Hoffbrand, and H. G. Prentice. 1993. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin. Infect. Dis. 17:397-404[Medline]. |
| 20. | Meier-Osusky, I., G. Schoedon, F. Blauer, M. Schneemann, and A. Schaffner. 1996. Comparison of the antimicrobial activity of deactivated human macrophages challenged with Aspergillus fumigatus and Listeria monocytogenes. J. Infect. Dis. 174:651-654[Medline]. |
| 21. |
Musial, C. E.,
F. R. Cockerill, and G. D. Roberts.
1988.
Fungal infections of the immunocompromised host: clinical and laboratory aspects.
Clin. Microbiol. Rev.
1:349-364 |
| 22. | Perfect, J. R., D. L. Granger, and D. T. Durack. 1987. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J. Infect. Dis. 156:316-323[Medline]. |
| 23. |
Purcell, I. F., and P. A. Corris.
1995.
Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.
Thorax
50:1321-1323 |
| 24. | Robertson, M. D., K. M. Kerr, and A. Seaton. 1989. Killing of Aspergillus fumigatus spores by human lung macrophages: a paradoxical effect of heat-labile serum components. J. Med. Vet. Mycol. 27:295-302[Medline]. |
| 25. |
Roilides, E.,
K. Uhlig,
D. Venzon,
P. A. Pizzo, and T. J. Walsh.
1993.
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.
Infect. Immun.
61:4870-4877 |
| 26. | Roilides, E., A. Holmes, C. Blake, D. Venzon, P. A. Pizzo, and T. J. Walsh. 1994. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J. Infect. Dis. 170:894-899[Medline]. |
| 27. | Roilides, E., A. Dimitriadou, I. Kadiltsoglou, T. Sein, J. Karpouzas, P. A. Pizzo, and T. J. Walsh. 1997. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J. Immunol. 158:322-329[Abstract]. |
| 28. | Rousey, S. R., S. Russler, M. Gottlieb, and R. C. Ash. 1991. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am. J. Med. 91:484-492[Medline]. |
| 29. | Schaffner, A. 1985. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J. Clin. Invest. 76:1755-1764. |
| 30. | Schaffner, A. 1992. Host defense in aspergillosis, p. 98-112. In J. E. Benett, R. J. Hay, and P. K. Peterson (ed.), New strategies in fungal disease. Churchill Livingstone, Edinburgh, United Kingdom. |
| 31. | Schaffner, A. 1994. Macrophage-Aspergillus interactions. Immunol. Ser. 60:545-552[Medline]. |
| 32. |
Schaffner, A.,
H. Douglas,
A. I. Braude, and C. E. Davis.
1983.
Killing of Aspergillus spores depends on the anatomical source of the macrophage.
Infect. Immun.
42:1109-1115 |
| 33. | Shihabi, Z. K., B. L. Wasilauskas, and J. E. Peacock. 1988. Serum amphotericin-B assay by scanning spectrophotometry. Ther. Drug Monit. 10:486-489[Medline]. |
| 34. | Stephan, J. L., V. Vlekova, F. Le Deist, S. Blanche, J. Donadieu, G. De Saint Basile, A. Durandy, C. Griscelli, and A. Fischer. 1993. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J. Pediatr. 123:564-572[Medline]. |
| 35. | Tanke, H. J., P. W. van der Linden, and J. Langerak. 1982. Alternative fluorochromes to ethidium bromide for automated read out of cytotoxicity tests. J. Immunol. Methods 52:91-96[Medline]. |
| 36. |
van Etten, E. W.,
N. E. van de Rhee,
K. M. van Kampen, and I. A. Bakker-Woudenberg.
1991.
Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.
Antimicrob. Agents Chemother.
35:2275-2281 |
| 37. |
Washburn, R. G.,
J. I. Gallin, and J. E. Bennett.
1987.
Oxidative killing of Aspergillus fumigatus proceeds by parallel myeloperoxidase-dependent and -independent pathways.
Infect. Immun.
55:2088-2092 |
| 38. | Washburn, R. G., C. H. Hammer, and J. E. Bennett. 1986. Inhibition of complement by culture supernatants of Aspergillus fumigatus. J. Infect. Dis. 154:944-951[Medline]. |
| 39. | Weller, U., L. Muller, M. Messner, M. Palmer, A. Valeva, J. Tranum-Jensen, P. Agrawal, C. Biermann, A. Dobereiner, M. A. Kehoe, and S. Bhakdi. 1996. Expression of active streptolysin O in Escherichia coli as a maltose-binding-protein-streptolysin-O fusion protein. The N-terminal 70 amino acids are not required for hemolytic activity. Eur. J. Biochem. 236:34-39[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»